Ikarian Capital’s Lipocine LPCN Stock Holding History

Ikarian Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Hold	508,556	–	–	0.14%	100
2026 Q1	$4.06M	Buy	508,556 +309,014	+155%	+$2.69M	0.33%	69
2025 Q4	$1.6M	Buy	+199,542	New	+$671K	0.13%	113

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

Ikarian Capital's LPCN Position: Q2 2026 in Review

Ikarian Capital held its Lipocine (LPCN) position steady in Q2 2026 at 508,556 shares worth $1.3M. The position accounts for 0.14% of the portfolio, ranked #100.

Ikarian Capital first reported a position in LPCN in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.06M in Q1 2026. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Ikarian Capital held 508,556 shares of Lipocine worth $1.3M as of Q2 2026.
Ikarian Capital left its Lipocine share count unchanged in Q2 2026.
Lipocine made up 0.14% of Ikarian Capital's portfolio in Q2 2026, its #100 holding.
Ikarian Capital first reported a position in Lipocine in Q4 2025 and has held it in 3 quarters since.
Ikarian Capital's Lipocine position peaked at $4.06M in Q1 2026.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.